Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06573281
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-26
Brief Title:
A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase 1 First-Time-in-Human FTiH Observer-blind Randomized Controlled Study to Evaluate the Safety Reactogenicity and Immune Response of Various Doses of an mRNA-based Respiratory Syncytial Virus RSV Investigational Vaccine in Healthy Participants 18-45 Years of Age
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the reactogenicity safety and immune response of various formulations of the RSV mRNA investigational vaccine administered in healthy participants 18-45 years of age
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None